ofloxacin has been researched along with caffeine in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.64) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 11 (23.40) | 29.6817 |
| 2010's | 24 (51.06) | 24.3611 |
| 2020's | 6 (12.77) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Andrisano, V; Arce, MP; Badia, A; Bartolini, M; Camps, P; Clos, MV; Dafni, T; Formosa, X; Galdeano, C; Gómez, E; Huertas, O; Isambert, N; Lavilla, R; Luque, FJ; Mancini, F; Muñoz-Torrero, D; Ramírez, L; Rodríguez-Franco, MI | 1 |
| Arce, MP; Conde, S; García, AG; González-Muñoz, GC; López, B; López, MG; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Sen, S; Sinha, N | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Brea, J; Cadavid, MI; Campillo, NE; Ceballos, P; Gil, C; Loza, MI; Martínez, A; Moro, MA; Pérez, C; Pérez, DI; Perez-Castillo, A; Redondo, M; Val, C; Zarruk, JG | 1 |
| Andrisano, V; Bolognesi, ML; Carloni, P; Cavalli, A; Chiriano, G; De Simone, A; Legname, G; Mancini, F; Martinez, A; Perez, DI; Roberti, M | 1 |
| Alonso-Gil, S; Campillo, NE; Castro, A; Encinas, A; Gil, C; Martinez, A; Morales-Garcia, JA; Palomo, V; Perez, C; Perez, DI; Perez-Castillo, A; Soteras, I | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Alonso-Gil, S; Chavarría, C; Gil, C; Morales Garcia, JA; Pérez, C; Perez, DI; Pérez-Castillo, A; Porcal, W; Souza, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bello, ML; Gil, C; Kraemer, BC; Lecourtois, M; Liachko, NF; Martinez, A; Miguel, L; Perez, C; Perez, DI; Redondo, M; Salado, IG | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, X; Xie, SS; Yu, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arce, MP; Conde, S; Egea, J; Gil, C; León, R; López, MG; Monjas, L; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Campillo, NE; Geiger, L; Gil, C; González, S; Li, L; Martinez, A; Morales, AV; Perez, DI; Salado, IG; Sebastián-Pérez, V; Zaldivar-Diez, J | 1 |
| Dong, SN; Gong, Q; Li, J; Li, XK; Liu, WW; Mao, F; Tang, Y; Wang, H; Wang, TD; Xu, YX; Zhang, HY; Zhu, J | 1 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Choi, HS; El-Gamal, MI; Gamal El-Din, MM; Han, DK; Jeon, HR; Kim, G; Kwon, D; Kwon, YJ; Lee, BS; Lee, JK; Lee, KH; Lee, KT; Mersal, KI; Oh, CH; Yoo, KH | 1 |
| Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
| Chaikuad, A; de Lago, E; Gil, C; Gomez-Almeria, M; Gonzalo-Consuegra, C; Knapp, S; Lietha, D; Martín-Requero, A; Martinez, A; Martínez-González, L; Monti, B; Nozal, V; Palomo, V; Pérez-Cuevas, E; Petralla, S; Ramírez, D; Santana, P | 1 |
| Barnett, G; Carbó, M; de la Torre, R; Segura, J | 1 |
| Harder, S; Papenburg, A; Staib, AH; Stille, W | 1 |
| Beer, C; Harder, S; Papenburg, A; Shah, PM; Staib, AH; Stille, W | 1 |
| Beer, C; Harder, S; Mieke, S; Shah, P; Staib, AH; Stille, W | 1 |
| Beer, C; Frech, K; Harder, S; Mieke, S; Shah, PM; Staib, AH; Stille, W | 1 |
| Beer, C; Dietlein, G; Harder, S; Mieke, S; Shah, PM; Staib, AH; Stille, W | 1 |
| Brain, RA; Hanson, ML; Johnson, DJ; Lam, MW; Mabury, SA; Richards, SM; Sanderson, H; Sibley, PK; Solomon, KR; Young, C | 1 |
| Hara, H; Yokoyama, A | 1 |
| Alonso, SG; Catalá, M; Maroto, RR; Martínez, F; Melero, JA; Molina, R; Rodríguez-Gil, JL; Segura, Y; Valcárcel, Y | 1 |
| Cao, Z; Li, X; Lu, Y; Mao, R; Song, S; Sun, B; Wang, C; Wang, R; Zhang, M | 1 |
| Farias, MAS; Fatibello-Filho, O; Moraes, FC; Santos, AM; Silva, RMS; Wong, A | 1 |
1 review(s) available for ofloxacin and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for ofloxacin and caffeine
| Article | Year |
|---|---|
4-quinolones inhibit biotransformation of caffeine.
Topics: Adult; Biotransformation; Caffeine; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Interactions; Enoxacin; Humans; Male; Molecular Structure; Norfloxacin; Ofloxacin; Pipemidic Acid; Quinolones; Random Allocation; Theophylline | 1988 |
Interaction between quinolones and caffeine.
Topics: Adult; Anti-Infective Agents; Caffeine; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Male; Middle Aged; Naphthyridines; Ofloxacin; Oxazines; Quinolines | 1987 |
44 other study(ies) available for ofloxacin and caffeine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Drug Design; Humans; Isomerism; Membranes, Artificial; Mice; Models, Molecular; Molecular Conformation; Permeability; Protein Binding; Tacrine | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catalytic Domain; Cattle; Cell Death; Cell Line, Tumor; Cell Survival; Cholinergic Agents; Cholinesterase Inhibitors; Esters; Glutamic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Neuroprotective Agents; Permeability; Piperidines; Protein Binding | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Permeability; Quinazolines; Stroke | 2012 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Survival; Chickens; Humans; Imidazoles; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Models, Molecular; Neurons; Small Molecule Libraries; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2012 |
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Blood-Brain Barrier; Cell Death; Cell Differentiation; Cell Membrane Permeability; Cells, Cultured; Glycogen Synthase Kinase 3; Hippocampus; Humans; Imines; In Vitro Techniques; Lipopolysaccharides; Membranes, Artificial; Microglia; Models, Molecular; Neural Stem Cells; Neurogenesis; Neurons; Neuroprotective Agents; Nitrites; Protein Binding; Rats; Structure-Activity Relationship; Substrate Specificity; Swine; Thiadiazoles | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood-Brain Barrier; Cell Survival; Dose-Response Relationship, Drug; Humans; Microwaves; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Peroxynitrous Acid; Structure-Activity Relationship; Tyrosine | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain Barrier; Casein Kinase I; Cell Membrane Permeability; Cells, Cultured; DNA-Binding Proteins; Drosophila; Drug Design; Drug Discovery; HEK293 Cells; Heterocyclic Compounds; High-Throughput Screening Assays; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Neurons; Neurotoxicity Syndromes; Phosphorylation; Protein Kinase Inhibitors; Substrate Specificity | 2014 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Coumarins; Drug Design; Erythrocytes; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Piperazines; Tacrine | 2015 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Donepezil; Glutamates; Hippocampus; Humans; Indans; Neuroprotective Agents; Piperidines; Rats; Solid-Phase Synthesis Techniques | 2017 |
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Neural Stem Cells; Neuroprotective Agents; Protein Kinase Inhibitors; Structure-Activity Relationship | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imidazoles; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Propylamines; Pyrimidines; Rats; Scopolamine; Structure-Activity Relationship; Thiourea | 2018 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Discovery of New Imidazo[2,1-
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Drug Stability; Half-Life; Humans; Imidazoles; Melanoma; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfonamides; Thiazoles; Transplantation, Heterologous | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spinal Cord; Tissue Distribution | 2022 |
Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.
Topics: Caffeine; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Male; Models, Biological; Norfloxacin; Ofloxacin; Pipemidic Acid; Quinolones | 1990 |
[Gyrase inhibitors modify metabolising processes in the liver].
Topics: Caffeine; Ciprofloxacin; DNA Topoisomerases, Type II; Enoxacin; Humans; Liver; Male; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pipemidic Acid; Topoisomerase II Inhibitors | 1987 |
Gyrase-inhibitors impair caffeine elimination in man.
Topics: Adult; Caffeine; Ciprofloxacin; Drug Interactions; Enoxacin; Humans; Kinetics; Male; Naphthyridines; Ofloxacin; Oxazines; Topoisomerase II Inhibitors | 1987 |
Decrease of caffeine elimination in man during co-administration of 4-quinolones.
Topics: Adult; Anti-Infective Agents; Caffeine; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Interactions; Enoxacin; Half-Life; Humans; Male; Naphthyridines; Ofloxacin; Oxazines; Quinolines | 1987 |
Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum.
Topics: Acetaminophen; Analysis of Variance; Atorvastatin; Biological Assay; Biomass; Caffeine; Carbamazepine; Complex Mixtures; Dose-Response Relationship, Drug; Heptanoic Acids; Heterocyclic Compounds; Levofloxacin; Magnoliopsida; Ofloxacin; Pharmaceutical Solutions; Pyrroles; Sertraline; Sulfamethoxazole; Toxicity Tests; Trimethoprim; Water Pollutants, Chemical | 2004 |
Multiple fixed drug eruption due to drug combination.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Bacterial Agents; Caffeine; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Levofloxacin; Ofloxacin; Patch Tests; Promethazine; Salicylamides | 2005 |
Heterogeneous photo-Fenton treatment for the reduction of pharmaceutical contamination in Madrid rivers and ecotoxicological evaluation by a miniaturized fern spores bioassay.
Topics: Biological Assay; Caffeine; Cotinine; Ecotoxicology; Ferns; Hydrogen Peroxide; Hydrogen-Ion Concentration; Iron; Miniaturization; Nicotine; Ofloxacin; Pharmaceutical Preparations; Rivers; Salicylic Acid; Spain; Water Pollutants, Chemical | 2010 |
Contamination, transport, and ecological risks of pharmaceuticals and personal care products in a large irrigation region.
Topics: Caffeine; China; Cosmetics; Ecosystem; Environmental Monitoring; Erythromycin; Humans; Norfloxacin; Ofloxacin; Pharmaceutical Preparations; Risk Assessment; Sulfamethoxazole; Water Pollutants, Chemical | 2022 |
Determination of ofloxacin in the presence of dopamine, paracetamol, and caffeine using a glassy carbon electrode based on carbon nanomaterials and gold nanoparticles.
Topics: Acetaminophen; Caffeine; Carbon; Chitosan; Dopamine; Electrodes; Gold; Graphite; Metal Nanoparticles; Ofloxacin; Pharmaceutical Preparations; Water | 2022 |